Mylan (MYL) stock price, revenue, and financials

Mylan market cap is $8.6 b, and annual revenue was $11.5 b in FY 2019

$8.6 B

MYL Mkt cap, 28-Jan-2021

$3 B

Mylan Revenue Q3, 2020
Mylan Gross profit (Q3, 2020)1.2 B
Mylan Gross profit margin (Q3, 2020), %39%
Mylan Net income (Q3, 2020)185.7 M
Mylan EBIT (Q3, 2020)351.4 M
Mylan Cash, 30-Sept-2020664.5 M
Mylan EV20.3 B
Get notified regarding key financial metrics and revenue changes at MylanLearn more
Banner background

Mylan Revenue

Mylan revenue was $11.5 b in FY, 2019 which is a 0.6% year over year increase from the previous period.

Embed Graph

Mylan Revenue Breakdown

Embed Graph

Mylan revenue breakdown by business segment: 16.0% from Central Nervous System & Anesthesia, 14.5% from Infectious Disease, 15.9% from Respiratory & Allergy, 7.8% from Cardiovascular, 10.0% from Gastroenterology, 7.3% from Diabetes & Metabolism, 6.3% from Women’s Health, 9.2% from Oncology and 13.0% from Other

Mylan revenue breakdown by geographic segment: 27.9% from Rest of World, 36.6% from North America and 35.5% from Europe

Mylan Income Statement

Mylan Balance Sheet

Annual

USDFY, 2017FY, 2018FY, 2019

Cash

292.1m388.1m475.6m

Accounts Receivable

3.6b2.9b3.1b

Prepaid Expenses

766.1m518.4m552.0m

Inventories

2.5b2.6b2.7b

Current Assets

7.2b6.4b6.8b

PP&E

2.3b2.2b2.1b

Goodwill

10.2b9.7b9.6b

Total Assets

35.8b32.7b31.3b

Accounts Payable

1.5b1.6b1.5b

Short-term debt

1.9b701.7m1.5b

Current Liabilities

6.4b4.6b5.6b

Long-term debt

12.9b13.2b11.2b

Total Debt

14.7b13.9b12.7b

Total Liabilities

22.5b20.6b19.4b

Common Stock

6.0m6.0m6.1m

Additional Paid-in Capital

8.6b8.6b8.6b

Retained Earnings

5.6b6.0b6.0b

Total Equity

13.3b12.2b11.9b

Debt to Equity Ratio

1.1 x1.1 x1.1 x

Debt to Assets Ratio

0.4 x0.4 x0.4 x

Financial Leverage

2.7 x2.7 x2.6 x

Mylan Cash Flow

Annual

USDFY, 2017FY, 2018FY, 2019

Net Income

696.0m352.5m16.8m

Depreciation and Amortization

1.8b2.1b2.0b

Accounts Receivable

(162.2m)340.1m(20.0m)

Inventories

(129.5m)(547.6m)(512.9m)

Accounts Payable

14.4m220.3m(96.3m)

Cash From Operating Activities

2.1b2.3b1.8b

Purchases of PP&E

(275.9m)(252.1m)(213.2m)

Cash From Investing Activities

(905.4m)(1.2b)(525.4m)

Short-term Borrowings

(2.9m)(44.4m)(1.8m)

Long-term Borrowings

(2.2b)(3.2b)(1.1b)

Cash From Financing Activities

(1.9b)(1.1b)(1.2b)

Net Change in Cash

(706.7m)19.4m101.8m

Interest Paid

474.0m460.8m470.6m

Income Taxes Paid

285.7m228.6m278.6m

Mylan Ratios

USDFY, 2017

EV/EBIT

25.8 x

EV/CFO

18 x

Revenue/Employee

340.2k

Debt/Equity

1.1 x

Debt/Assets

0.4 x

Financial Leverage

2.7 x

P/E Ratio

32.5

Mylan Operating Metrics

FY, 2017FY, 2018FY, 2019

Products

7.5 k7.5 k7.5 k

Countries

165165165

Products (Cardiovascular)

1.15 k1.15 k

Products (Dermatology)

500500

Products (Gastroenterology)

700700

Products (Infectious Disease)

1.1 k1.1 k

Products (Respiratory)

600600

Products (Women's Health)

650650

Products (Anesthesia)

1.9 k1.9 k

Products (Diabetes & Metabolism)

450450

Patents Issued

4.5 k5 k

Products (Immunology)

8080

Products (Oncology)

450450

Products in Pipeline (Anesthesia)

550400

Products in Pipeline (Cardiovascular Disease)

320300

Products in Pipeline (Dermatology)

6060

Products in Pipeline (Diabetes & Metabolism)

300250

Products in Pipeline (Gastroenterology)

150100

Products in Pipeline (Immunology)

10075

Products in Pipeline (Infectious Disease)

900800

Products in Pipeline (Oncology)

550500

Products in Pipeline (Respiratory & Allergy)

150150

Products in Pipeline (Women’s Health)

150150

Research and Development Centers

1212

Mylan Sustainability Metrics

 FY, 2019

Water Used (Rainwater)

1 k cubic meters

Water Used (Other)

3 k cubic meters

Water Used (On-Site Borewell)

100 k cubic meters

Water Used (Municipal)

3.16 m cubic meters

Water Recycled

475 k cubic meters

Water Discharged

1.57 m cubic meters

Water Consumed

3.26 m cubic meters

Waste Recycled, percent

74%

Waste Generated

69 k tonnes

Total Recordable Incident Rate

0.67

Total Greenhouse Gas Emissions

670 k tonnes

Total Energy Used

611 GWh

Number of Fatalities

0

Nonhazardous Waste Generated

24 k tonnes

Lost Time Incident Rate

0.41

Hazardous Waste Generated

45 k tonnes

Greenhouse Gas Emissions Intensity

58 tonnes per million USD revenue

Greenhouse Gas Emissions (Scope 2)

354 k tonnes

Greenhouse Gas Emissions (Scope 1)

316 k tonnes

Energy Used from Renewable Energy Sources

90 GWh

Energy Used from Non-renewable Energy Sources

521 GWh

Energy Intensity Ratio

0.05 GWh per million USD revenue

Dart Rate

0.47

Mylan Human Capital

Gender

FY, 2018FY, 2017
Female, percent9.9%9.4%
Female (Management), percent8.9%8.7%
Male (Board), percent22.2%21.3%
Female (Board), percent11.1%12%
Male, percent23.4%23.9%
Male (Management), percent24.4%24.7%

Job Roles

FY, 2018FY, 2017
Scientific Affairs, percent8.2%8.6%
Management and Administration, percent13.7%13.7%
Sales and Marketing, percent21%19.7%
Operations, percent57.1%58%

Mylan Employee Rating

3.6902 votes
Culture & Values
3.3
Work/Life Balance
3.3
Senior Management
3.1
Salary & Benefits
3.8
Career Opportunities
3.5
Source